Advice
in the absence of a submission from the holder of the marketing authorisation
lapatinib (Tyverb ®) is not recommended for use within NHS Scotland.
Indication under review: treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice78KB (PDF)
Medicine details
- Medicine name:
- lapatinib (Tyverb)
- SMC ID:
- 925/13
- Indication:
- Treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 November 2013